Cost-effectiveness analysis is an increasingly important tool for healthcare decision-making in the context of increasing budgetary constraints, an ever-increasing range of treatment options and the relatively high price of new treatments.1-3
THERAKOS ECP ImmunomodulationTM has been shown to be cost effective in the treatment of both acute and chronic graft-versus-host disease (GvHD).3-5
In addition, studies show that THERAKOS ECP Immunomodulation™ may help avoid the costs associated with immunosuppressing the patient.3,5,6
Cost effectiveness in
acute GvHD
In acute GvHD, THERAKOS ECP ImmunomodulationTM has been proven cost-effective in adults4
See data from Poland
Walczak 2012 (Poland)1

*Sub group analysis not representative of the entire study population.
**The CE threshold is an ICER threshold below which an intervention is deemed cost effective. CE, cost-effectiveness; HSCT, haematopoietic stem cell transplantation; ICER, incremental cost-effectiveness ratio; LY, life-year; PLN, Polish Zloty (currency of Poland). 1. Walczak J, et al. Value Health. 2012;15:A349.
Cost effectiveness in
chronic GvHD
In chronic GvHD, THERAKOS ECP ImmunomodulationTM has been proven cost-effective in adults and children3-5,7
See data from Italy
De Waure 2015 (Italy)1

*Sub group analysis not representative of the entire study population.
**Compared with alternatives, a treatment or intervention is ‘dominant’ when it is both more effective and less costly. HSCT, haematopoietic stem cell transplantation; ICUR, incremental cost-utility ratio; QALY, quality-adjusted life year. 1. de Waure C, et al. Value Health. 2015;18(4):457-466.
See data from Poland
Walczak 2012 (Poland)1

*Sub group analysis not representative of the entire study population.
**The CE threshold is an ICER threshold below which an intervention is deemed cost effective. CE, cost-effectiveness; HSCT, haematopoietic stem cell transplantation; ICER, incremental cost-effectiveness ratio; LY, life-year; PLN, Polish Zloty (currency of Poland). 1. Walczak J, et al. Value Health. 2012;15:A349.
See data from Spain
Crespo 2016 (Spain)1

*The CE threshold is an ICUR threshold below which an intervention is deemed cost effective.
†Compared with alternatives, a treatment or intervention is ‘dominant’ when it is both more effective and less costly.
CE, cost-effectiveness; HSCT, haematopoietic stem cell transplantation; ICUR, incremental cost-utility ratio; QALY, quality-adjusted life year.
1. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787.
See data from the UK
York Health Economics Consortia 2006 (UK)1

*Sub group analysis not representative of the entire study population.
**The CE threshold is an ICUR threshold below which an intervention is deemed cost effective. CE, cost-effectiveness; HSCT, haematopoietic stem cell transplantation; ICUR, incremental cost-utility ratio; QALY, quality-adjusted life year.
1. THERAKOS™, data on file.
References:
1. Hill SR. BMC Med. 2012;10:10; 2. Eichler HG, et al. Value Health. 2004;7(5):518-528; 3. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787; 4. Walczak J, et al. Value Health. 2012;15:A349; 5. de Waure C, et al. Value Health. 2015;18(4):457-466; 6. Knobler R, et al. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1:1-37; 7. THERAKOS™, data on file.